All In Biotech

NDA 220736 · Galderma Labs Lp

Differin Epiduo Acne Gel (Adapalene and Benzoyl Peroxide)

Adapalene, Benzoyl Peroxide, Adapalene, Benzoyl Peroxide · Topical · Retinoid

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

May 22, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

112

28 Phase 3, 7 recruiting

FAERS reports

54

22 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 20, 2026.

Use For the treatment of acne

Therapeutic areas: Ophthalmology · Dermatology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 22, 2026 Original approval · Type 8 - Partial Rx to OTC Switch LetterLabel
4 products under this application
  • DIFFERIN EPIDUO ACNE GEL (ADAPALENE AND BENZOYL PEROXIDE) · ADAPALENE, BENZOYL PEROXIDE 45G · GEL, · Over-the-counter
  • DIFFERIN EPIDUO ACNE GEL (ADAPALENE AND BENZOYL PEROXIDE) · ADAPALENE, BENZOYL PEROXIDE 15G · GEL, · Over-the-counter
  • DIFFERIN EPIDUO ACNE GEL (ADAPALENE AND BENZOYL PEROXIDE) · ADAPALENE, BENZOYL PEROXIDE 30G · GEL, · Over-the-counter
  • DIFFERIN EPIDUO · ADAPALENE 0.1%; BENZOYL PEROXIDE 2.5% · GEL, TOPICAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Adapalene" as an intervention, any sponsor and status, largest first.

All 112 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective9
  • rash6
  • acne4
  • erythema4
  • application site pain3
  • application site pruritus3
  • burning sensation3
  • pruritus3
  • application site erythema2
  • application site irritation2
  • dermatitis atopic2
  • drug hypersensitivity2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20132
20142
20151
20161
20171
20181
20197
20207
20213
20223
20236
202410
20257
20263

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 219 on PubMed

Sponsor: Galderma Labs Lp · Also marketed as Differin Epiduo

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.